Study Of ATRN-119 In Patients With Advanced Solid Tumors

Exclusion Criteria

• •Patient has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.
• •Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.
• •Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.
• •Known human immunodeficiency virus infection (HIV).
• •Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.
• •Current or past diagnosis of leukemia within the past 5 years.
• •Prior radiotherapy at the target lesion unless there is evidence of disease progression.
• •Known CNS metastases or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging \[MRI\] brain).
• •History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.
• •Patient has uncontrolled hypertension at time of enrollment.
• •Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block \[RBBB\] with either left anterior hemiblock or left posterior hemiblock).
• •Any clinically significant ST segment and/or T-wave abnormalities.
• •Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.